![](https://scx1.b-cdn.net/csz/news/tmb/2024/phase-iii-clinical-tri.jpg)
Phase III trial shows lorlatinib highly effective against ALK-positive non–small cell lung cancer
A large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is highly effective for treating non–small cell lung cancer (NSCLC).